newsfilter
← Latest News
GlobeNewswire·

Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026

  • Krystal Biotech will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets.
  • Management will host a conference call & webcast at 8:30 am ET on November 2, 2026, to discuss financial results & provide a business update.
  • The live webcast is accessible at https://www.webcaster5.com/Webcast/Page/3018/54689.
  • A replay of the webcast will be available for at least 30 days on the Investors section of www.krystalbio.com.
  • Krystal Biotech is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on genetic medicines.
  • The Company's first commercial product, VYJUVEK®, is the first redosable gene therapy approved in the U.S., Europe, & Japan for dystrophic epidermolysis bullosa.
  • Stéphane Paquette, PhD, serves as the contact for investors & media at spaquette@krystalbio.com.